Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMF )

9.681 UNCHANGED
Streaming Delayed Price Updated: 10:51 AM EST, Nov 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astellas Pharma Inc

< Previous 1 2 Next >
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
Via Benzinga
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... 
Via Benzinga
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo. 
Via Benzinga
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant... 
Via Benzinga
Astellas' Menopause Drug Under FDA Review
Via Benzinga
Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say
Via Benzinga
Sutro Biopharma Stock Surges On Cancer Treatment Pact
Via Benzinga
Why Is Seagen Stock Trading Higher Today?
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC:  
Via Benzinga
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected  
Via Benzinga
Why Shares of Adaptive Biotechnologies Jumped This Week
The company could see its first FDA-approved therapy as early as next year. 
Via The Motley Fool
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as  
Via Benzinga
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
By David Willey, Benzinga 
Via TheNewswire.com
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? 
Via News Direct
Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold
Via Benzinga
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio 
Via Benzinga
Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
Bloomberg 
Via Benzinga
Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
The FDA on Friday approved Japanese drugmaker Astellas Pharma Inc’s (OTC: ALPMY) (OTC: ALPMF) Veozah (fezolinetant) for hot flashes 
Via Benzinga
Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
Astellas Pharma Inc (OTC: ALPMY) and Pfizer Inc (NYSE: PFE) announced  
Via Benzinga
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of  
Via Benzinga
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
Via Benzinga
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
Via Benzinga
Japanese Government Urges China To Release Astellas Pharma's Employee
The Japanese government is reportedly seeking the release of an employee of Japanese pharma company Astellas Pharma Inc (OTC: ALPMF), detained by Chinese authorities.  The reasons why the person was... 
Via Benzinga
Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
Via Benzinga
Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts
Via Benzinga
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Via Benzinga
Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs
Via Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial
Via Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.